Emerging Therapies for the Older Patient With Acute Lymphoblastic Leukemia

Author(s):

Gregory W. Roloff, MDJae Park, MD

Dr. Shah and faculty provide updates on emerging therapies, which exhibit promise for the treatment of relapsed or refractory acute lymphoblastic leukemia such as tisagenlecleucel and Obe-cel; obecabtagene autoleucel, preliminary outcomes of which were presented in the FELIX study at the 65th ASH Annual Meeting.

EP: 1.Faculty Introductions

EP: 2.Objectives of the 2023 ASH Insights Program on CAR-T Cell Therapy for Adult B Cell ALL

EP: 3.Overview of the Current State of CART19 Therapy for Adult Patients With R/R ALL

EP: 4.Objectives, Clinical Endpoints, and Safety Profile of the Phase 2 ZUMA-3 Clinical Trial

EP: 5.Progression-Free Survival, Overall Survival, and the Prognostic Significance of Negative Minimal Residual Disease

EP: 6.Standardizing and Optimizing Bridging Strategies Prior to CAR-T Infusion

EP: 7.Outcomes of the Retrospective, Multicenter ROCCA Analysis (Real-World Outcomes Collaborative of CAR-T in Adult ALL)

EP: 8.Influences on Treatment Response and Survival in Recipients of Brexucabtagene Autoleucel Therapy

EP: 9.Optimal Sequencing of Therapy for Previously Treated Patients With Relapsed or Refractory ALL

Now Viewing